Home

Home

article image

Development of potential Hepatitis C vaccine

The British Midlands’ University of Nottingham discovered a possible vaccine for use in the treatment of Hepatits C. At the 161st. meeting of the Society for General Microbiology in Edinburgh, UK, a paper titled “Human Antibodies to Hepatits C Virus – Potential for Vaccine Design” was presented.

Approximately 150-200 million people worldwide are infected with the Hepatitis C virus. The infection often results in chronic hepatitis which can lead to cirrhosis of the liver and liver cancer. Hepatits C is the most common reason for liver transplantation in both the US and UK. At present, there is no vaccination that protects against contracting Hepatitis C.

Now a research group analyzed antibodies that have potential to successfully prevent infection with Hepatitis C. In laboratory models the antibodies proved to be effective against many diverse strains of the virus. The HCV is classified into six major genotypes with an existing 30 subtypes.

“The clinical potential of this work cannot be overstated. Historically, successful vaccines against viruses have required the production of antibodies, and this is likely to be the case for Hepatitis C virus. Identifying regions of the virus that are able to induce broadly reactive neutralizing antibodies is a significant milestone in the development of a HCV vaccine, which will have distinct healthcare benefits for hepatitis sufferers, and could also help us design vaccines for other chronic viral diseases such as HIV,” said Dr. Alexander Tarr, a Research Fellow at Nottingham's Institute of Infection, Immunity and Inflammation, during the presentation.

"We are also currently exploring the possibility of improving liver transplantation success rates by passively infusing people with these antibodies. Additionally we are using the information gained by identifying and characterizing the antibody responses to Hepatitis C virus to design new ways of making vaccine candidates. If the antibodies we have discovered can be reproduced by vaccination, control of the disease might be possible," concludes Dr. Tarr.

This article was published on 09/18/2007

Search

 

Service

Company News

Carestream: technical infrastructure for EU funded R-bay project

Carestream Health is a major technical infrastructure provider to the EU-funded R-Bay validation project, which aims to address the uneven spread of radiologists across member states. CARESTREAM Radiology and Information Management Solutions are driving the initial test platform for the project by facilitating remote reporting of images from hospitals in Denmark, Finland and Czech Republic by clinical providers in Estonia, Lithuania and the Netherlands.

Insulin in oral capsules

At the international congress on diabetes in September, Oramed Pharmaceuticals, Inc. introduced its oral insulin capsules that might in the future replace injections patients currently have to face. Last week Oramed announced the agreement with ETI Karle Clinical Pvt. Ltd. to conduct phase 2B clinical trials for its oral insulin capsules.

Products redesigned to help patients simplify life with diabetes

Bayer HealthCare Diabetes Care unveiled the new
CONTOUR® blood glucose meter with enhanced testing features at the 44th Annual Meeting of the European Association for the Study of Diabetes in Rome, Italy.